{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:09:19Z","timestamp":1793236159220,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["cstc2021jcyj-msxmX1129"],"award-info":[{"award-number":["cstc2021jcyj-msxmX1129"]}],"id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]},{"name":"he High-level Medical Reserved Personnel Training Project of Chongqing","award":["2020GDRC012c"],"award-info":[{"award-number":["2020GDRC012c"]}]},{"name":"the Chongqing Entrepreneurship and Innovation Support Program for Overseas Students Returning to China","award":["cx2019102"],"award-info":[{"award-number":["cx2019102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Systemic sclerosis (SSc) is an immune-mediated rheumatic disease characterized by fibrosis and vascular lesions. Interstitial lung disease is an early complication of SSc and the main cause of death from SSc. Although baricitinib shows good efficacy in a variety of connective tissue diseases, its role in systemic sclerosis-related interstitial lung disease (SSc-ILD) is unclear. The objective of our study was to explore the effect and mechanism of baricitinib in SSc-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We explored crosstalk between the JAK2 and TGF-\u03b21 pathways. In vivo experiments, SSc-ILD mice model were constructed by subcutaneous injection of PBS or bleomycin (7.5\u00a0mg\/kg) and intragastric administration of 0.5% CMC-Na or baricitinib (5\u00a0mg\/kg) once every two days. We used ELISA, qRT\u2012PCR, western blot and immunofluorescence staining to evaluate the degree of fibrosis. In vitro experiments, we used TGF-\u03b21 and baricitinib to stimulate human fetal lung fibroblasts (HFLs) and assessed protein expression by western blot.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The vivo experiments showed that baricitinib notably alleviated skin and lung fibrosis, decreased the concentration of pro-inflammatory factors and increased those of the anti-inflammatory factors. Baricitinib affected the expression of TGF-\u03b21 and T\u03b2RI\/II inhibitiing JAK2. In the vitro experiments, following the culture of HFLs with baricitinib or a STAT3 inhibitor for 48\u00a0h, the expression levels of T\u03b2RI\/II decreased. Conversely, with successful inhibition of TGF-\u03b2 receptors in HFLs, JAK2 protein expression decreased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baricitinib attenuated bleomycin-induced skin and lung fibrosis in SSc-ILD mice model by targeting JAK2 and regulating of the crosstalk between the JAK2 and TGF-\u03b21 signaling pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-023-00305-3","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T05:04:57Z","timestamp":1684213497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Crosstalk between the JAK2 and TGF-\u03b21 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib"],"prefix":"10.1186","volume":"63","author":[{"given":"Dandan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-3933","authenticated-orcid":false,"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"issue":"10103","key":"305_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399.","journal-title":"Lancet"},{"issue":"3","key":"305_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304\u201320.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"305_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Tse CLY, Burry L, et al. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020;40(8):843\u201356.","journal-title":"Pharmacotherapy"},{"issue":"10","key":"305_CR4","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/jcph.1874","volume":"61","author":"S Assadiasl","year":"2021","unstructured":"Assadiasl S, Fatahi Y, Mosharmovahed B, et al. Baricitinib: from rheumatoid arthritis to COVID-19. J Clin Pharmacol. 2021;61(10):1274\u201385.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"305_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384(9):795\u2013807.","journal-title":"N Engl J Med"},{"issue":"4","key":"305_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2144\/000112729","volume":"44","author":"RH H\u00fcbner","year":"2008","unstructured":"H\u00fcbner RH, Gitter W, El Mokhtari NE, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44(4):507\u201311.","journal-title":"Biotechniques"},{"issue":"15","key":"305_CR7","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.3390\/molecules26154491","volume":"26","author":"H Ruan","year":"2021","unstructured":"Ruan H, Luan J, Gao S, et al. Fedratinib attenuates bleomycin-induced pulmonary fibrosis via the JAK2\/STAT3 and TGF-beta1 signaling pathway. Molecules. 2021;26(15):4491.","journal-title":"Molecules"},{"issue":"12","key":"305_CR8","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.3390\/ijms22126211","volume":"22","author":"P Montero","year":"2021","unstructured":"Montero P, Milara J, Roger I, et al. Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms. Int J Mol Sci. 2021;22(12):6211.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"305_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12931-018-0728-9","volume":"19","author":"J Milara","year":"2018","unstructured":"Milara J, Hernandez G, Ballester B, et al. The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):24.","journal-title":"Respir Res"},{"issue":"6","key":"305_CR10","doi-asserted-by":"publisher","first-page":"e22336","DOI":"10.1096\/fj.202101436R","volume":"36","author":"S Wang","year":"2022","unstructured":"Wang S, Liu M, Li X, et al. Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. FASEB J. 2022;36(6):e22336.","journal-title":"FASEB J"},{"issue":"8","key":"305_CR11","doi-asserted-by":"publisher","first-page":"e12952","DOI":"10.1111\/jfbc.12952","volume":"43","author":"RA Eid","year":"2019","unstructured":"Eid RA, Alkhateeb MA, El-Kott AF, et al. A high-fat diet rich in corn oil induces cardiac fibrosis in rats by activating JAK2\/STAT3 and subsequent activation of ANG II\/TGF-1beta\/Smad3 pathway: the role of ROS and IL-6 trans-signaling. J Food Biochem. 2019;43(8):e12952.","journal-title":"J Food Biochem"},{"issue":"1","key":"305_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12906-020-03180-3","volume":"21","author":"T Qin","year":"2021","unstructured":"Qin T, Wu Y, Liu T, et al. Effect of Shenkang on renal fibrosis and activation of renal interstitial fibroblasts through the JAK2\/STAT3 pathway. BMC Complement Med Ther. 2021;21(1):12.","journal-title":"BMC Complement Med Ther"},{"key":"305_CR13","doi-asserted-by":"publisher","first-page":"153552","DOI":"10.1016\/j.phymed.2021.153552","volume":"87","author":"Q Ren","year":"2021","unstructured":"Ren Q, Tao S, Guo F, et al. Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6\/JAK2\/STAT3 and TGF-beta\/SMAD3 signaling. Phytomedicine. 2021;87:153552.","journal-title":"Phytomedicine"},{"issue":"6","key":"305_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/thoraxjnl-2017-210728","volume":"73","author":"J Milara","year":"2018","unstructured":"Milara J, Ballester B, Morell A, et al. JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study. Thorax. 2018;73(6):519\u201329.","journal-title":"Thorax"},{"key":"305_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fonc.2018.00287","volume":"8","author":"E Bousoik","year":"2018","unstructured":"Bousoik E, Montazeri AH. \u201cDo We Know Jack\u201d about JAK? A closer look at JAK\/STAT signaling pathway. Front Oncol. 2018;8:287.","journal-title":"Front Oncol"},{"issue":"6","key":"305_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3109\/08977194.2011.614949","volume":"29","author":"FA Zouein","year":"2011","unstructured":"Zouein FA, Duh\u00e9 RJ, Booz GW. JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. Growth Factors. 2011;29(6):245\u201352.","journal-title":"Growth Factors"},{"key":"305_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cyto.2016.12.017","volume":"91","author":"J Fischer","year":"2017","unstructured":"Fischer J, Silva TE, Soares ESPE, et al. From stable disease to acute-on-chronic liver failure: circulating cytokines are related to prognosis in different stages of cirrhosis. Cytokine. 2017;91:162\u20139.","journal-title":"Cytokine"},{"issue":"1","key":"305_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12931-020-1319-0","volume":"21","author":"G Epstein Shochet","year":"2020","unstructured":"Epstein Shochet G, Brook E, Bardenstein-Wald B, et al. TGF-\u03b2 pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Respir Res. 2020;21(1):56.","journal-title":"Respir Res"},{"issue":"5","key":"305_CR19","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3892\/ijo.2014.2310","volume":"44","author":"RY Liu","year":"2014","unstructured":"Liu RY, Zeng Y, Lei Z, et al. JAK\/STAT3 signaling is required for TGF-\u03b2-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol. 2014;44(5):1643\u201351.","journal-title":"Int J Oncol"},{"issue":"1","key":"305_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1096\/fj.15-273953","volume":"30","author":"M Pedroza","year":"2016","unstructured":"Pedroza M, Le TT, Lewis K, et al. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. Faseb J. 2016;30(1):129\u201340.","journal-title":"Faseb J"},{"issue":"14","key":"305_CR21","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.7150\/thno.32352","volume":"9","author":"W Chen","year":"2019","unstructured":"Chen W, Yuan H, Cao W, et al. Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation. Theranostics. 2019;9(14):3980\u201391.","journal-title":"Theranostics"},{"issue":"9","key":"305_CR22","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/gutjnl-2016-313392","volume":"67","author":"DM Xiang","year":"2018","unstructured":"Xiang DM, Sun W, Ning BF, et al. The HLF\/IL-6\/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 2018;67(9):1704\u201315.","journal-title":"Gut"},{"issue":"11","key":"305_CR23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798\u2013809.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"305_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s12890-020-01336-y","volume":"20","author":"J Wang","year":"2020","unstructured":"Wang J, Zheng P, Huang Z, et al. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features. BMC Pulm Med. 2020;20(1):315.","journal-title":"BMC Pulm Med"},{"issue":"8","key":"305_CR25","doi-asserted-by":"publisher","first-page":"a022053","DOI":"10.1101\/cshperspect.a022053","volume":"8","author":"CH Heldin","year":"2016","unstructured":"Heldin CH, Moustakas A. Signaling receptors for TGF-beta family members. Cold Spring Harb Perspect Biol. 2016;8(8):a022053.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"305_CR26","doi-asserted-by":"publisher","first-page":"a022293","DOI":"10.1101\/cshperspect.a022293","volume":"10","author":"KK Kim","year":"2018","unstructured":"Kim KK, Sheppard D, Chapman HA. TGF-beta1 signaling and tissue fibrosis. Cold Spring Harb Perspect Biol. 2018;10(4):a022293.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"305_CR27","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1096\/fj.201901719RR","volume":"34","author":"DM Hernandez","year":"2020","unstructured":"Hernandez DM, Kang JH, Choudhury M, et al. IPF pathogenesis is dependent upon TGFbeta induction of IGF-1. FASEB J. 2020;34(4):5363\u201388.","journal-title":"FASEB J"},{"issue":"32","key":"305_CR28","doi-asserted-by":"publisher","first-page":"23337","DOI":"10.1074\/jbc.M700194200","volume":"282","author":"M Zeisberg","year":"2007","unstructured":"Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem. 2007;282(32):23337\u201347.","journal-title":"J Biol Chem"},{"key":"305_CR29","first-page":"301","volume":"7","author":"IA Darby","year":"2014","unstructured":"Darby IA, Laverdet B, Bonte F, et al. Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Investig Dermatol. 2014;7:301\u201311.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"33","key":"305_CR30","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/onc.2015.446","volume":"35","author":"G Wang","year":"2016","unstructured":"Wang G, Yu Y, Sun C, et al. STAT3 selectively interacts with Smad3 to antagonize TGF-beta signalling. Oncogene. 2016;35(33):4388\u201398.","journal-title":"Oncogene"},{"issue":"5","key":"305_CR31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/annrheumdis-2013-204256","volume":"74","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Dees C, Beyer C, et al. Inhibition of casein kinase II reduces TGF\u03b2 induced fibroblast activation and ameliorates experimental fibrosis. Ann Rheum Dis. 2015;74(5):936\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"305_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","volume":"26","author":"Q Lv","year":"2020","unstructured":"Lv Q, Wang J, Xu C, et al. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt\/GSK-3beta\/beta-catenin and TGF-beta1\/Smad2\/3 signaling pathways. Mol Med. 2020;26(1):49.","journal-title":"Mol Med"},{"issue":"3","key":"305_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0014-5793(01)02258-X","volume":"492","author":"T Yamamoto","year":"2001","unstructured":"Yamamoto T, Matsuda T, Muraguchi A, et al. Cross-talk between IL-6 and TGF-beta signaling in hepatoma cells. FEBS Lett. 2001;492(3):247\u201353.","journal-title":"FEBS Lett"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00305-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-023-00305-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00305-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T05:10:06Z","timestamp":1684213806000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-023-00305-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1186\/s42358-023-00305-3","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Ethics Committee of Chengdu Dashuo Biotechnology Co. (Dossy20210119001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}